IPG-CANDESARTAN TABLET

Negara: Kanada

Bahasa: Inggris

Sumber: Health Canada

Bahan aktif:

CANDESARTAN CILEXETIL

Tersedia dari:

MARCAN PHARMACEUTICALS INC

Kode ATC:

C09CA06

INN (Nama Internasional):

CANDESARTAN

Dosis:

4MG

Bentuk farmasi:

TABLET

Komposisi:

CANDESARTAN CILEXETIL 4MG

Rute administrasi :

ORAL

Unit dalam paket:

30/100/1000

Jenis Resep:

Prescription

Area terapi:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Ringkasan produk:

Active ingredient group (AIG) number: 0135220001; AHFS:

Status otorisasi:

APPROVED

Tanggal Otorisasi:

2016-08-19

Karakteristik produk

1
PRODUCT MONOGRAPH
PR
IPG-CANDESARTAN
Candesartan Cilexetil Tablets
4 mg, 8 mg, 16 mg and 32 mg
Angiotensin II AT
1
Receptor Blocker
Date of Preparation:
August 19, 2016
Marcan Pharmaceuticals Inc.
77 Auriga Drive, Suite #4
Ottawa, Ontario
K2E 7Z7
CONTROL# 196962
2
TABLE OF CONTENTS
CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
...........................................................................................
3
SUMMARY PRODUCT INFORMATION
........................................................................................................
3
INDICATIONS AND CLINICAL
USE................................................................................................................
3
CONTRAINDICATIONS
.................................................................................................................................
4
WARNINGS AND PRECAUTIONS
.................................................................................................................
4
ADVERSE REACTIONS
.................................................................................................................................
8
DRUG INTERACTIONS
...............................................................................................................................
14
DOSAGE AND ADMINISTRATION
..............................................................................................................
17
OVERDOSAGE
...........................................................................................................................................
20
ACTION AND CLINICAL PHARMACOLOGY
................................................................................................
20
STORAGE AND
STABILITY..........................................................................................................................
23
DOSAGE FORMS, COMPOSITION AND PACKAGING
.................................................................................
23
PART II: SCIENTIFIC INFORMATION
.....................